Quest Diagnostics Upgrades EPS Outlook For 2026 After Outperforming Q2 Results

Quest Diagnostics earns a reiterated buy rating after Q2 earnings beat, upgraded FY guidance, and continued market momentum. DGX benefits from strong macro demand for specialized diagnostic testing, peer-leading ROE, and resilient top-line growth (+10.2% YoY). Upward earnings revisions, robust dividend growth, and investment-grade credit ratings support the bull case, though cost pressures and payor risk warrant monitoring.

Seeking Alpha • 15 hours ago

Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • 11 hours ago

Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • 10 hours ago

Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) is a Great Choice

Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • 8 hours ago

Quest Diagnostics raises annual forecast on testing demand

Quest Diagnostics on Thursday raised its full-year profit forecast, after demand for routine diagnostic testing helped ​the company beat second-quarter estimates.

Reuters • Jul 23, 2026

Quest Diagnostics Surges After Hims- And Oura-Tied Beat

Quest Diagnostics put up a definitive beat Thursday, driven by solid demand across its consumer division, leading the stock to surge.

Investors Business Daily • Jul 23, 2026

Quest Diagnostics Q2 Earnings Call Highlights

Quest Diagnostics NYSE: DGX reported double-digit revenue growth and raised its full-year 2026 outlook after what executives described as strong demand across its physician, hospital and consumer channels, as well as increased volume from major collaborations with Corewell Health and Fresenius Medical Care.

MarketBeat • Jul 23, 2026

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growth Second quarter reported diluted earnings per share ("EPS") of $2.84, up 15.0% from 2025; and adjusted diluted EPS of $3.12, up 19.1% from 2025 Full year 2026 revenues now expected to be between $11.95 billion and $12.05 billion Full year 2026 reported diluted EPS now expected to be between $9.97 and $10.17; and adjusted diluted EPS expected to be between $11.05 and $11.25 SECAUCUS, N.J., July 23, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2026.

PRNewsWire • Jul 23, 2026

Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning

Quest Diagnostics Incorporated (NYSE:DGX) stock surged Thursday after the diagnostic testing company reported second-quarter results that topped Wall Street expectations and raised its full-year 2026 guidance.

Benzinga • Jul 23, 2026

Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call Transcript

Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 23, 2026